XGN is expected to report earnings to rise 12.61% to -31 cents per share on March 24
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.18
Q1'24
Beat
by $0.17
Q4'23
Beat
by $0.12
The last earnings report on November 12 showed earnings per share of -28 cents, beating the estimate of -28 cents. With 65.80K shares outstanding, the current market capitalization sits at 27.06M.
a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases